STXS Stereotaxis

Stereotaxis to Report Second Quarter Financial Results on August 9, 2022

Stereotaxis to Report Second Quarter Financial Results on August 9, 2022

ST. LOUIS, July 19, 2022 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2022 second quarter on Tuesday, August 9, 2022 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10 a.m. ET that day to discuss the Company’s results and corporate developments.

What:  Stereotaxis second quarter 2022 financial results conference call
  
When:Tuesday, August 9, 2022 at 10:00 a.m. ET (7:00 a.m. PT)
  
Dial In Number:To access the live call, dial 888-394-8218 (US and Canada) or 1-856-344-9221 (International) and give the participant pass code 9211068.
  
Webcast:To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at
  
Call Replay:A phone replay of the call will be available for one month beginning approximately two hours following the end of the call. To request access for a replay of the conference call, please .

About Stereotaxis

 (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit

Investor Contacts:

David L. Fischel

Chairman and Chief Executive Officer		Media Contact:

Bethanne Schluter

Director, Marketing & Communications
  
Kimberly Peery

Chief Financial Officer		 
  
314-678-6100

 
  


EN
19/07/2022

Underlying

STXSStereotaxis

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Stereotaxis

 PRESS RELEASE
Free
STXS STEREOTAXIS

Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Resu...

Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Results on March 9, 2026 ST. LOUIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 fourth quarter and full year on Monday, March 9, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments. What:Stereotaxis fourth quarter and full ...

February 12, 2026 1 EN
 PRESS RELEASE
Free
STXS STEREOTAXIS

Klinikum Fürth Establishes Leading Robotic Heart Arrhythmia Program

Klinikum Fürth Establishes Leading Robotic Heart Arrhythmia Program ST. LOUIS, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the launch of a new robotic electrophysiology program at Klinikum Fürth in Fürth, Germany. Klinikum Fürth is the first hospital in Germany to establish a leading heart rhythm program that incorporates the Genesis Robotic Magnetic Navigation System, advanced robotic technology that establishes a new standard of care for patients with arrhy...

February 9, 2026 1 EN
 PRESS RELEASE
Free
STXS STEREOTAXIS

Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter

Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter ST. LOUIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained U.S. Food and Drug Administration (FDA) approval for the MAGiC™ Magnetic Interventional Ablation Catheter. “FDA approval of MAGiC is a significant milestone for Stereotaxis and the community of physicians pioneering robotics in electrophysiology. It ensures the benefits of Robotic Magnetic Navigation can support patients with comple...

January 6, 2026 1 EN
 PRESS RELEASE
Free
STXS STEREOTAXIS

Stereotaxis to Participate in Piper Sandler 37th Annual Healthcare Con...

Stereotaxis to Participate in Piper Sandler 37th Annual Healthcare Conference ST. LOUIS, Nov. 24, 2025 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the company will participate in the . David Fischel, Stereotaxis Chairman and CEO, is scheduled to participate in a fireside discussion on Wednesday, December 3rd, 2025, at 9:00 am Eastern Standard Time and will be available that same day for one-on-one meetings. “This is an exciting period for Stereotaxis as we achieve key regulator...

November 24, 2025 1 EN
 PRESS RELEASE
Free
STXS STEREOTAXIS

Stereotaxis Reports 2025 Third Quarter Financial Results

Stereotaxis Reports 2025 Third Quarter Financial Results ST. LOUIS, Nov. 11, 2025 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2025. “We continue to focus on driving commercial progress while advancing a robust portfolio of technologies through regulatory and development milestones,” said David Fischel, Chairman and CEO. “This is an exciting milestone-rich period in which we are demonstrating the tangible reality and initial...

November 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch